DOCSLIB.ORG

Identification of a Novel HADHB Gene Mutation in an Iranian Patient With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of a Novel HADHB Gene Mutation in an Iranian Patient With ,GHQWLÀFDWLRQRID1RYHOHADHB Gene Mutation Original Article ,GHQWL¿FDWLRQRID1RYHOHADHB Gene Mutation in an Iranian 3DWLHQWZLWK0LWRFKRQGULDO7ULIXQFWLRQDO3URWHLQ'H¿FLHQF\ Mahdiyeh Shahrokhi MSc10RKDPPDG6KD¿HL3K'1, Hamid Galehdari PhD1, Gholamreza Shariati PhDƔ Abstract Introduction:0LWRFKRQGULDOWULIXQFWLRQDOSURWHLQ 073 LVDKHWHURRFWDPHUFRPSRVHGRIHLJKWSDUWV VXEXQLWV IRXUĮVXEXQLWVFRQWDLQLQJ /&(+ ORQJFKDLQHQR\O&R$K\GUDWDVH DQG/&+$' ORQJFKDLQK\GUR[\DF\O&R$GHK\GURJHQDVH DFWLYLW\DQGIRXUȕVXEXQLWVWKDW SRVVHVV/&.7 ORQJFKDLQNHWRDF\O&R$WKLRODVH DFWLYLW\ZKLFKFDWDO\]HV three out of four steps in ȕoxidation spiral of longchain fatty acid. Its GH¿FLHQF\ is an autosomal recessive disorder that causes a clinical spectrum of diseases. Materials and Methods: A blood spot was collected from the patient’s original newborn screening card with parental informed consent. A newborn screening test and quantity plasma acylcarnitine SUR¿OH analysis by MSMS were performed. After isolation of '1$ and $PSOL¿FDWLRQ of all exons of the HADHA and HADHB, directly Sequence analyses of all exons and the ÀDQNLQJ introns both of genes were performed. Result: Here, we report a novel mutation in a patient with 073 GH¿FLHQF\ diagnosed with newborn screening test and quantity plasma acylcarnitine SUR¿OH analysis by MSMS and then FRQ¿UPHG by HQ]\PH analysis in cultured ¿EUREODVWV and direct sequencing of the HADHA and HADHB genes. Molecular analysis of causative genes showed a missense mutation p.43 c.$ > C in exon of HADHB gene. Conclusions: Since this mutation was not found in normal control cases; so it was concluded that c.$ > C mutation was a causative mutation. Phenotype analysis of this mutation predicted pathogenesis which reduces the stability of the 073 protein complex. Keywords: 'H¿FLHQF\, fatty acid oxidation, HADHA, HADHB, mitochondrial trifunctional protein 073 novel mutation Cite this article as: 6KDKURNKL06KD¿HL0*DOHKGDUL+6KDULDWL*,GHQWL¿FDWLRQRIDQRYHOHADHB gene mutation in an Iranian patient with mitochondrial WULIXQFWLRQDOSURWHLQGH¿FLHQF\Arch Iran Med. 2017; 20(1): 22 – 27. Introduction that causes a clinical spectrum of diseases.4 Symptoms of mitochondrial trifunctional protein GH¿FLHQF\ may present in atty acid oxidation is the main source of energy for heart infancy or later in life. Features that occur during infancy comprise and muscles. Mitochondrial Trifunctional Protein lack of energy (lethargy), feeding GLI¿FXOWLHV, hypoketotic F (M-FTP) is bound to the inner mitochondrial membrane hypoglycemia provoked by prolonged fasting, weak muscle tone which catalyzes three out of four steps in ȕ-oxidation of long- (hypotonia), lactic acidemia, acute renal failure, and fulminant chain fatty. This protein is a hetero-octamer composed of eight liver failure. That patients who present in infancy are also at high parts (subunits): four Į-subunits containing LCEH (long-chain risk for breathing GLI¿FXOWLHV, serious heart problems, coma, and 2,3-enoyl-CoA hydratase) and LCHAD (long-chain 3-hydroxyacyl sudden unexplained infant death. Some patients survive into CoA dehydrogenase) activity, and four ȕ-subunits that possess adolescence and adulthood with hypotonia, muscle aches, LCKT (long-chain 3-ketoacyl-CoA thiolase) activity.1 M-TFP damaged skeletal muscle tissue (Rhabdomyolysis) and impaired GH¿FLHQF\ is FODVVL¿HG into 2 phenotypes: the more prevalent sensation in the extremities (peripheral neuropathy).5 The most isolated LCHAD GH¿FLHQF\ (OMIM: 609016) with defects of the common defect of mitochondrial trifunctional protein is isolated Į-subunits encoded by the HADHA (OMIM: 600890) LCHAD GH¿FLHQF\ (LCHADD), and it occurs when the activity (hydroxyacyl-CoA dehydrogenase Į-subunit) gene and the less of the enzyme “long chain 3-hydroxyacyl-CoA dehydrogenase” common pattern of complete M-TFP GH¿FLHQF\ (OMIM: (LCHAD) is reduced with substantial preservation of the other 609015).2 Generally, all 3 enzyme activities of the M-FTP two MTP enzymatic activities.6 complex are undetectable in M-FTP GH¿FLHQF\ due to defects of The incidence of LCHAD GH¿FLHQF\ is unknown and this both HADHA and HADHB (hydroxyacyl-CoA dehydrogenase disorder can occur in anyone of any ethnic background.7 Based ß-subunit) genes (OMIM: 143450).3 HADHA and HADHB genes on an American population, it is estimated at approximately 1 are located in the same region on chromosome 2p23 (Respectively in 75,000, with a calculated carrier frequency of 1 in 138.8 In ENSG00000084754, ENSG00000138029). Mitochondrial Europe, the prevalence is probably much lower, approximately trifunctional protein GH¿FLHQF\ is an autosomal recessive disorder 1 in 100,000.8 More than 60% of patients with LCHADD have the E474Q (c.1528G > C) mutation in the gene encoding the $XWKRUV¶ DI¿OLDWLRQV 1Department of Genetics, Faculty of Science, Shahid alpha-subunit of the mitochondrial trifunctional protein. E474Q 2 Chamran University, Ahvaz, Iran, Narges Medical Genetic Laboratory, Ahvaz, mutation replaces a glutamic acid with the glutamine at position Iran, 3Department of Medical Genetics, Jundishapur University of Medical Science, Ahvaz, Iran. 474 in the active site of LCHAD that is located in the C-terminal •Corresponding author and reprints: Gholamreza Shariati PhD, Narges domain.9 The other defect of mitochondrial trifunctional protein Medical Genetic Laboratory, Ahvaz, Iran, Department of Medical Genetics, is complete M-TFP GH¿FLHQF\ in which the activities of all Jundishapur University of Medical Science, Ahvaz, Iran. Tel: 0661-3336681, E-mail: [email protected] three enzymes of the complex are disrupted. Complete M-TFP Accepted for publication: 23 November 2016 22 Archives of Iranian Medicine, Volume 20, Number 1, January 2017 06KDKURNKL06KDÀHL+*DOHKGDULHWDO GH¿FLHQF\ (TFPD) is a rare disorder and far less common than performed with reverse primers. Finally, to predict the possible the LCHADD.5 Despite the clinical and phenotypic similarities effects of the observed mutations, an online software was used. between these two disorders, there are some distinct differences Approved software of SIFT, Mutation Taster, Polyphen-2 and in data from screening patients by tandem mass spectrometry PANTHER were used to predict disease-causing mutation. Also, and biochemical and genetic analysis can distinguish between To predict the effects of mutations on protein stability based on LCHADD and TFPD when compared to each other.10 This article the sequence, I-Mutant and MuStab software were used. To verify describes the clinical and biochemical ¿QGLQJV of a patient with the effect of this mutation on tertiary structure of the protein, the M-TFP GH¿FLHQF\ and one novel mutation of the HADHB genes. Swiss model software was used and three-dimensional structure of proteins was rebuilt by Swiss model. Materials and Methods Results The male patient was the second born to consanguine parents in Iran. His parents were asymptomatic. They were heterozygous Acylcarnitine analysis of blood spots showed prominent in terms of mutation but without any pretense of decease. In fact, accumulation of long chain hydroxylated acylcarnitines, as based on all the studies, individuals heterozygous for this disease follows: 3-OH-palmitoylcarnitine (C16-OH), 0.76 μmol/L (RR < do not have any clinical symptoms. The newborn patient suffered 0.08 μmol/L); 3-OH-oleylcarnitine (C18:1-OH), 0.34 μmol/L (RR IURPDVSK\[LDWLRQZKLOHQXUVLQJLQWKH¿UVWPRQWKRIKLVELUWK < 0.1) (Figure 1a). In addition, the level of tetradecenoylcarnitine He eventually died of multi-organ failure at 25 days of age. His (C14:1), 0.32 μmol/L (RR < 0.25) was midly elevated. clinical symptoms included cardiomyopathy, hepatopathy and The concentration of free carnitine was normal: 34 μmol/L hypoketotic hypoglycemia. A blood spot from the patient was PHWKRG ZLWK GHULYLWLVDWLRQ 55 ± ȝPRO/ )LJXUH D collected from the patient’s original newborn screening card Therefore, a disorder of long chain hydroxylated fatty acid with parental informed consent. All ethical considerations such R[LGDWLRQ /&+$'7)3GH¿FLHQF\ /RQJ &KDLQ +\GUR[\ODWHG as parental and all case-control consent form to maintain patient $F\O&R$'HK\GURJHQDVH7ULIXQFWLRQDO3URWHLQGH¿FLHQF\ ZDV data were included in this study. A questionnaire was distributed suspected. to all controls and patient’s family. Acylcarnitines were extracted The results of electromyography and skeletal muscle biopsy with methanol and then derivatized with butanolic HCl. Butylated pathologic analysis in this study were not available. Since acylcarnitines were analyzed by tandem mass spectrometry. the newborn had a serious problems and died earlier, it was Urine organic acids and plasma amino acids were analyzed. For impossible to obtain this data and the parents were not available; DNA mutation analysis, a blood spot (5 mL) was collected from so that this Electroretinogram could be performed on them. the patient and his parents. After isolation of DNA by standard DNA analysis using genomic DNA revealed a novel homozygous salting out method from peripheral blood leukocytes, the quality missense mutation in the HADHB gene of the patient with MTP RIH[WUDFWHG'1$ZDVFRQ¿UPHGXVLQJJHOHOHFWURSKRUHVLV7KHQ GH¿FLHQF\EHORQJLQJWRWKHVHFRQGSKHQRW\SH7KHSDWLHQWKDGD the 20 exons and adjacent intronic consensus splice sites of the homozygous missense mutation“c.1154A > C - cDNA.1258A > HADHA and 16 exon of the HADHB JHQH ZHUH DPSOL¿HG E\ C - g.41718A > C” mutations in the HADHB gene (Figure 1b). polymerase chain reaction. Sixteen sets of primers for HADHB The c.1154A > C transition resulted
Load more

Recommended publications
  • Diapositiva 1
    ns 10 A Unmethylated C Methylated ) 8 Normal Normal Tissue Cervix Esophagus 4 cervical esophageal a.u. * *** * *** ( 6 TargetID MAPINFO Position Ca-Ski HeLa SW756 tissue COLO-680N KYSE-180 OACM 5.1C tissue cg04255070 22851591 TSS1500 0.896 0.070 0.082 0.060 0.613 0.622 0.075 0.020 2 (log2) 4 cg01593340 22851587 TSS1500 0.826 0.055 0.051 0.110 0.518 0.518 0.034 0.040 cg16113692 22851502 TSS200 0.964 0.073 0.072 0.030 0.625 0.785 0.018 0.010 2 0 cg26918510 22851422 TSS200 0.985 0.019 0.000 0.000 0.711 0.961 0.010 0.060 expression cg26821579 22851416 TSS200 0.988 0.083 0.058 0.000 0.387 0.955 0.021 0.050 TRMT12 mRNA Expression mRNA TRMT12 0 cg01129966 22851401 TSS200 0.933 0.039 0.077 0.020 0.815 0.963 0.078 0.010 -2 cg25421615 22851383 TSS200 0.958 0.033 0.006 0.000 0.447 0.971 0.037 0.020 mRNA cg17953636 22851321 1stExon 0.816 0.092 0.099 0.080 0.889 0.750 0.136 0.030 -4 Methylated SVIP Unmethylated SVIP relative expression (a.u.) expression relative SVIP D Cervix Esophagus HNC Meth ) HNC Unmeth Cervix Meth 3.0 *** Cervix Unmeth *** Esophagus Meth a.u. ( 2.5 CaCaEsophagus-Ski-Ski Unmeth COLO-680N Haematological Meth TSS B TSS Haematological Unmeth 2.0 -244 bp +104 bp 244 bp +104 bp 1.5 ** * expression -SVIP 1.0 HeLa KYSE-180 HeLa TSS TSS 0.5 -ACTB 244 bp +104 bp - 244 bp +104 bp mRNA 0.0 HeLa SW756 Ca-Ski SW756 SW756 OACM 5.1C TSS KYSE-180 TSS COLO-680NOACM 5.1 C - 244 bp +104 bp 244 bp +104 bp E ) 3.0 * Ca-Ski COLO-680N WT TSS TSS 2.0 a.u.
    [Show full text]
  • Altered Expression and Function of Mitochondrial Я-Oxidation Enzymes
    0031-3998/01/5001-0083 PEDIATRIC RESEARCH Vol. 50, No. 1, 2001 Copyright © 2001 International Pediatric Research Foundation, Inc. Printed in U.S.A. Altered Expression and Function of Mitochondrial ␤-Oxidation Enzymes in Juvenile Intrauterine-Growth-Retarded Rat Skeletal Muscle ROBERT H. LANE, DAVID E. KELLEY, VLADIMIR H. RITOV, ANNA E. TSIRKA, AND ELISA M. GRUETZMACHER Department of Pediatrics, UCLA School of Medicine, Mattel Children’s Hospital at UCLA, Los Angeles, California 90095, U.S.A. [R.H.L.]; and Departments of Internal Medicine [D.E.K., V.H.R.] and Pediatrics [R.H.L., A.E.T., E.M.G.], University of Pittsburgh School of Medicine, Magee-Womens Research Institute, Pittsburgh, Pennsylvania 15213, U.S.A. ABSTRACT Uteroplacental insufficiency and subsequent intrauterine creased in IUGR skeletal muscle mitochondria, and isocitrate growth retardation (IUGR) affects postnatal metabolism. In ju- dehydrogenase activity was unchanged. Interestingly, skeletal venile rats, IUGR alters skeletal muscle mitochondrial gene muscle triglycerides were significantly increased in IUGR skel- expression and reduces mitochondrial NADϩ/NADH ratios, both etal muscle. We conclude that uteroplacental insufficiency alters of which affect ␤-oxidation flux. We therefore hypothesized that IUGR skeletal muscle mitochondrial lipid metabolism, and we gene expression and function of mitochondrial ␤-oxidation en- speculate that the changes observed in this study play a role in zymes would be altered in juvenile IUGR skeletal muscle. To test the long-term morbidity associated with IUGR. (Pediatr Res 50: this hypothesis, mRNA levels of five key mitochondrial enzymes 83–90, 2001) (carnitine palmitoyltransferase I, trifunctional protein of ␤-oxi- dation, uncoupling protein-3, isocitrate dehydrogenase, and mi- Abbreviations tochondrial malate dehydrogenase) and intramuscular triglycer- CPTI, carnitine palmitoyltransferase I ides were quantified in 21-d-old (preweaning) IUGR and control IUGR, intrauterine growth retardation rat skeletal muscle.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (Cad) by Phosphorylation and Protein-Protein Interactions
    THE REGULATION OF CARBAMOYL PHOSPHATE SYNTHETASE-ASPARTATE TRANSCARBAMOYLASE-DIHYDROOROTASE (CAD) BY PHOSPHORYLATION AND PROTEIN-PROTEIN INTERACTIONS Eric M. Wauson A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology. Chapel Hill 2007 Approved by: Lee M. Graves, Ph.D. T. Kendall Harden, Ph.D. Gary L. Johnson, Ph.D. Aziz Sancar M.D., Ph.D. Beverly S. Mitchell, M.D. 2007 Eric M. Wauson ALL RIGHTS RESERVED ii ABSTRACT Eric M. Wauson: The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (CAD) by Phosphorylation and Protein-Protein Interactions (Under the direction of Lee M. Graves, Ph.D.) Pyrimidines have many important roles in cellular physiology, as they are used in the formation of DNA, RNA, phospholipids, and pyrimidine sugars. The first rate- limiting step in the de novo pyrimidine synthesis pathway is catalyzed by the carbamoyl phosphate synthetase II (CPSase II) part of the multienzymatic complex Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, Dihydroorotase (CAD). CAD gene induction is highly correlated to cell proliferation. Additionally, CAD is allosterically inhibited or activated by uridine triphosphate (UTP) or phosphoribosyl pyrophosphate (PRPP), respectively. The phosphorylation of CAD by PKA and ERK has been reported to modulate the response of CAD to allosteric modulators. While there has been much speculation on the identity of CAD phosphorylation sites, no definitive identification of in vivo CAD phosphorylation sites has been performed. Therefore, we sought to determine the specific CAD residues phosphorylated by ERK and PKA in intact cells.
    [Show full text]
  • Isocitrate Dehydrogenase Activity Assay Kit (MAK062)
    Isocitrate Dehydrogenase Activity Assay Kit Catalog Number MAK062 Storage Temperature –20 C TECHNICAL BULLETIN Product Description Developer 1 vl Isocitrate dehydrogenase (IDH) catalyzes the Catalog Number MAK062E conversion of isocitrate to -ketoglutarate. In eukaryotes, there are three isozymes of IDH, the IDH Positive Control (NADP+) 20 L mitochondrial IDH2 and IDH3, and the cytoplasmic/ Catalog Number MAK062F peroxisomal IDH1. All three IDH family members require the presence of a divalent cation (Mg2+ or Mn2+) NADH Standard, 0.5 mole 1 vl and either the electron-accepting cofactor NADP+ (IDH1 Catalog Number MAK062G and IDH2) or NAD+ (IDH3) for their enzymatic activity. IDH1 and IDH2 mutations resulting in neomorphic Reagents and Equipment Required but Not enzymatic activity are found in certain cancers such as Provided. glioblastoma, acute myeloid leukemia, and colon 96 well flat-bottom plate – It is recommended to use cancer. This neoactivity shows a change in the clear plates for colorimetric assays. substrate specificity resulting in the conversion of Spectrophotometric multiwell plate reader -ketoglutarate to 2-hydroxyglutarate. Mutations in IDH family members are also associated with Ollier disease Precautions and Disclaimer and Maffucci syndrome. This product is for R&D use only, not for drug, household, or other uses. Please consult the Material The Isocitrate Dehydrogenase Activity Assay kit Safety Data Sheet for information regarding hazards provides a simple and direct procedure for measuring and safe handling practices. + + + NADP -dependent, NAD -dependent, or both NADP + and NAD -dependent IDH activity in a variety of Preparation Instructions samples. IDH activity is determined using isocitrate as Briefly centrifuge vials before opening.
    [Show full text]
  • Role of De Novo Cholesterol Synthesis Enzymes in Cancer Jie Yang1,2, Lihua Wang1,2, Renbing Jia1,2
    Journal of Cancer 2020, Vol. 11 1761 Ivyspring International Publisher Journal of Cancer 2020; 11(7): 1761-1767. doi: 10.7150/jca.38598 Review Role of de novo cholesterol synthesis enzymes in cancer Jie Yang1,2, Lihua Wang1,2, Renbing Jia1,2 1. Department of Ophthalmology, Ninth People’s Hospital of Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China. Corresponding authors: Renbing Jia, [email protected] and Lihua Wang, [email protected]. Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, No. 639 Zhi Zao Ju Road, Shanghai 200011, China © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.07.21; Accepted: 2019.11.30; Published: 2020.01.17 Abstract Despite extensive research in the cancer field, cancer remains one of the most prevalent diseases. There is an urgent need to identify specific targets that are safe and effective for the treatment of cancer. In recent years, cancer metabolism has come into the spotlight in cancer research. Lipid metabolism, especially cholesterol metabolism, plays a critical role in membrane synthesis as well as lipid signaling in cancer. This review focuses on the contribution of the de novo cholesterol synthesis pathway to tumorigenesis, cancer progression and metastasis. In conclusion, cholesterol metabolism could be an effective target for novel anticancer treatment. Key words: metabolic reprogramming, de novo cholesterol synthesis, cancer progress Introduction Over the past few decades, numerous published that cholesterol plays a critical role in cancer studies have focused on cancer cell metabolism and progression15-19.
    [Show full text]
  • Isocitrate Dehydrogenase 1 (NADP+) (I5036)
    Isocitrate Dehydrogenase 1 (NADP+), human recombinant, expressed in Escherichia coli Catalog Number I5036 Storage Temperature –20 °C CAS RN 9028-48-2 IDH1 and IDH2 have frequent genetic alterations in EC 1.1.1.42 acute myeloid leukemia4 and better understanding of Systematic name: Isocitrate:NADP+ oxidoreductase these mutations may lead to an improvement of (decarboxylating) individual cancer risk assessment.6 In addition other studies have shown loss of IDH1 in bladder cancer Synonyms: IDH1, cytosolic NADP(+)-dependent patients during tumor development suggesting this may isocitrate dehydrogenase, isocitrate:NADP+ be involved in tumor progression and metastasis.7 oxidoreductase (decarboxylating), Isocitric Dehydrogenase, ICD1, PICD, IDPC, ICDC, This product is lyophilized from a solution containing oxalosuccinate decarboxylase Tris-HCl, pH 8.0, with trehalose, ammonium sulfate, and DTT. Product Description Isocitrate dehydrogenase (NADP+) [EC 1.1.1.42] is a Purity: ³90% (SDS-PAGE) Krebs cycle enzyme, which converts isocitrate to a-ketoglutarate. The flow of isocitrate through the Specific activity: ³80 units/mg protein glyoxylate bypass is regulated by phosphorylation of isocitrate dehydrogenase, which competes for a Unit definition: 1 unit corresponds to the amount of 1 common substrate (isocitrate) with isocitrate lyase. enzyme, which converts 1 mmole of DL-isocitrate to The activity of the enzyme is dependent on the a-ketoglutarate per minute at pH 7.4 and 37 °C (NADP formation of a magnesium or manganese-isocitrate as cofactor). The activity is measured by observing the 2 complex. reduction of NADP to NADPH at 340 nm in the 7 presence of 4 mM DL-isocitrate and 2 mM MnSO4.
    [Show full text]
  • RESEARCH COMMUNICATION HADHA Is a Potential Predictor Of
    HADHA is a Potential Predictor of the Response to Platinum-based Chemotherapy RESEARCH COMMUNICATION HADHA is a Potential Predictor of Response to Platinum-based Chemotherapy for Lung Cancer Taihei Kageyama1, Ryo Nagashio1, 2, Shinichiro Ryuge 3, Toshihide Matsumoto1,5, Akira Iyoda4, Yukitoshi Satoh4, Noriyuki Masuda3, Shi-Xu Jiang5, Makoto Saegusa5, Yuichi Sato1, 2* Abstract To identify a cisplatin resistance predictor to reduce or prevent unnecessary side effects, we firstly established four cisplatin-resistant sub-lines and compared their protein profiles with cisplatin-sensitive parent lung cancer cell lines using two-dimensional gel electrophoresis. Between the cisplatin-resistant and -sensitive cells, a total of 359 protein spots were differently expressed (>1.5 fold), and 217 proteins (83.0%) were identified. We focused on a mitochondrial protein, hydroxyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme A hydratase alpha subunit (HADHA), which was increased in all cisplatin-resistant cells. Furthermore, pre- treated biopsy specimens taken from patients who showed resistance to platinum-based treatment showed a significantly higher positive rate for HADHA in all cases (p=0.00367), including non-small cell lung carcinomas (p=0.002), small-cell lung carcinomas (p=0.038), and adenocarcinomas (p=0.008). These results suggest that the expression of HADHA may be a useful marker to predict resistance to platinum-based chemotherapy in patients with lung cancer. Keywords: Cisplatin - HADHA - lung cancer - two-dimensional gel electrophoresis Asian Pacific J Cancer Prev, 12, 3457-3463 Introduction cisplatin resistance rose due to a decrease of blood flow in the tumor and increased DNA repair (Stewart, 2007), Lung cancer is the leading cause of cancer-related the mechanisms underlying cisplatin resistance have not death in the world, and the five-year overall survival rate yet been clarified, and an effective cisplatin resistance is still below 16% (Jemal et al., 2009).
    [Show full text]
  • Health Effects Support Document for Perfluorooctanoic Acid (PFOA)
    United States Office of Water EPA 822-R-16-003 Environmental Protection Mail Code 4304T May 2016 Agency Health Effects Support Document for Perfluorooctanoic Acid (PFOA) Perfluorooctanoic Acid – May 2016 i Health Effects Support Document for Perfluorooctanoic Acid (PFOA) U.S. Environmental Protection Agency Office of Water (4304T) Health and Ecological Criteria Division Washington, DC 20460 EPA Document Number: 822-R-16-003 May 2016 Perfluorooctanoic Acid – May 2016 ii BACKGROUND The Safe Drinking Water Act (SDWA), as amended in 1996, requires the Administrator of the U.S. Environmental Protection Agency (EPA) to periodically publish a list of unregulated chemical contaminants known or anticipated to occur in public water systems and that may require regulation under SDWA. The SDWA also requires the Agency to make regulatory determinations on at least five contaminants on the Contaminant Candidate List (CCL) every 5 years. For each contaminant on the CCL, before EPA makes a regulatory determination, the Agency needs to obtain sufficient data to conduct analyses on the extent to which the contaminant occurs and the risk it poses to populations via drinking water. Ultimately, this information will assist the Agency in determining the most appropriate course of action in relation to the contaminant (e.g., developing a regulation to control it in drinking water, developing guidance, or deciding not to regulate it). The PFOA health assessment was initiated by the Office of Water, Office of Science and Technology in 2009. The draft Health Effects Support Document for Perfluoroctanoic Acid (PFOA) was completed in 2013 and released for public comment in February 2014.
    [Show full text]
  • Maturation of Sucrase-Isomaltase Complex in Human Fetal Small and Large Intestine During Gestation
    136 TRIADOU AND ZWEIBAUM 003 1-3998/85/190 1-0 136$02.0010 PEDIATRIC RESEARCH Vol. 19, No. 1, 1985 Copyright O 1985 International Pediatric Research Foundation, Inc Prin~edin U.S. A. Maturation of Sucrase-Isomaltase Complex in Human Fetal Small and Large Intestine during Gestation NICOLE TRIADOU AND ALAIN ZWEIBAUM UnitP de Recherches de GPnetique MPdicale [N. T.], INSERM U 12, H6pital des Enfants Malades, and Unite de Recherches sur le MPtabolisme et la Diffirmciation des Cellules en Culture [A.Z.],INSERM U 178, H6pital Broussais, Paris, France ABSTRACT. Sucrase-isomaltase complex is expressed in chromatography. The homogeneity of the preparation was as- human small intestine throughout gestation and in the large sessed by polyacrylamide gel electrophoresis and crossed immu- intestine between 12 and 30 wk. The molecular form of the noelectrophoresis against an antihuman brush-border antiserum enzyme was studied in the brush-border membrane frac- (12). Rabbits were immunized by sc injections at 15-day intervals tions by the immunoblotting method. Before 30 wk of with 0.2 mg of purified enzyme and bled 7 days after the fourth gestation, the enzyme is present only as the high molecular injection. Immunoglobulins G were prepared by ion exchange weight prosucrase-isomaltase, while from 30 wk until birth chromatography (10, 15). the two subunits are also present. The fetal enzyme, as its Brush-border separation, transjer, and identification of antigen. proform and as its two subunits, has a faster mobility in Preparations of the brush-border fractions of small and large sodium-dodecylsulfate polyacrylamide gel electrophoresis, intestine were obtained by the calcium precipitation method as than the adult enzyme (removal of sialic acid residues from previously described (12).
    [Show full text]
  • (LCHAD) Deficiency / Mitochondrial Trifunctional Protein (MTF) Deficiency
    Long chain acyl-CoA dehydrogenase (LCHAD) deficiency / Mitochondrial trifunctional protein (MTF) deficiency Contact details Introduction Regional Genetics Service Long chain acyl-CoA dehydrogenase (LCHAD) deficiency / mitochondrial trifunctional Levels 4-6, Barclay House protein (MTF) deficiency is an autosomal recessive disorder of mitochondrial beta- 37 Queen Square oxidation of fatty acids. The mitochondrial trifunctional protein is composed of 4 alpha London, WC1N 3BH and 4 beta subunits, which are encoded by the HADHA and HADHB genes, respectively. It is characterized by early-onset cardiomyopathy, hypoglycemia, T +44 (0) 20 7762 6888 neuropathy, and pigmentary retinopathy, and sudden death. There is also an infantile F +44 (0) 20 7813 8578 onset form with a hepatic Reye-like syndrome, and a late-adolescent onset form with primarily a skeletal myopathy. Tandem mass spectrometry of organic acids in urine, Samples required and carnitines in blood spots, allows the diagnosis to be unequivocally determined. An 5ml venous blood in plastic EDTA additional clinical complication can occur in the pregnant mothers of affected fetuses; bottles (>1ml from neonates) they may experience maternal acute fatty liver of pregnancy (AFLP) syndrome or Prenatal testing must be arranged hypertension/haemolysis, elevated liver enzymes and low platelets (HELLP) in advance, through a Clinical syndrome. Genetics department if possible. The genes encoding the HADHA and HADHB subunits are located on chromosome Amniotic fluid or CV samples 2p23.3. The pathogenic
    [Show full text]
  • Lipid Metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
    cancers Review Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives 1, 1, 1 2 1 Laurence Pellerin y, Lorry Carrié y , Carine Dufau , Laurence Nieto , Bruno Ségui , 1,3 1, , 1, , Thierry Levade , Joëlle Riond * z and Nathalie Andrieu-Abadie * z 1 Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, Université Fédérale de Toulouse Midi-Pyrénées, Université Toulouse III Paul-Sabatier, Inserm 1037, 2 avenue Hubert Curien, tgrCS 53717, 31037 Toulouse CEDEX 1, France; [email protected] (L.P.); [email protected] (L.C.); [email protected] (C.D.); [email protected] (B.S.); [email protected] (T.L.) 2 Institut de Pharmacologie et de Biologie Structurale, CNRS, Université Toulouse III Paul-Sabatier, UMR 5089, 205 Route de Narbonne, 31400 Toulouse, France; [email protected] 3 Laboratoire de Biochimie Métabolique, CHU Toulouse, 31059 Toulouse, France * Correspondence: [email protected] (J.R.); [email protected] (N.A.-A.); Tel.: +33-582-7416-20 (J.R.) These authors contributed equally to this work. y These authors jointly supervised this work. z Received: 15 September 2020; Accepted: 23 October 2020; Published: 27 October 2020 Simple Summary: Melanoma is a devastating skin cancer characterized by an impressive metabolic plasticity. Melanoma cells are able to adapt to the tumor microenvironment by using a variety of fuels that contribute to tumor growth and progression. In this review, the authors summarize the contribution of the lipid metabolic network in melanoma plasticity and aggressiveness, with a particular attention to specific lipid classes such as glycerophospholipids, sphingolipids, sterols and eicosanoids.
    [Show full text]